Notably, a comprehensive study used ASOs to target LINC00624 in HER2+ BC, resulting in the inhibition of proliferation in vitro and increasing the expression of innate immune response-related genes in xenograft tumor models, supporting the role of LINC00624 as an inhibitor of the antitumoral immune response (76). This evidence concerns the gene ERBB2 and breast cancer.